SVP, Finance · Maze Therapeutics, Inc. · Maze Therapeutics, Inc. — Stock Option (Right to Buy)
Side
M
Value
—
Shares
2,503
Price
—
Executed
Jan 22, 2026
Disclosed
Jan 26, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jan 22 executedJan 26, 2026 disclosed
MAZE · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Option exercise — administrative, little informational value
Relative size+9 / 25
No reported dollar value · 46.6% of prior position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+4 / 15
5 prior trades recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Maze Therapeutics, Inc. — Stock Option (Right to Buy)
Ticker
MAZE
Shares
2,503
Price per share
$0
Execution date (reported)
Jan 22, 2026
Owned after transaction
7,869 shares
Rule 10b5-1 plan
Yes, as checked by the filer
Days from execution to publication
4
What this establishes
Bachrodt Amy filed this Form 4 reporting a option exercise of MAZE on Jan 22, 2026. It became public on Jan 26, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
SVP, Finance
Bachrodt Amycik:0002050422
Issuer
Maze Therapeutics, Inc.cik:0001842295
Revision history · 0
No field has changed since this record was first ingested.
